by John Conrad | May 13, 2024 | Member News
In a promising development for Alzheimer’s research, Takeda Pharmaceutical Company and AC Immune SA announced a collaboration to develop and commercialize a new treatment approach. The agreement focuses on ACI-24.060, an active immunotherapy candidate designed...
by John Conrad | Apr 23, 2020 | COVID, Member News
As the COVID-19 crisis continues to unfold, Takeda’s Patient Assistance Response team is working around the clock to help ensure that the people who need our medicines and treatments can continue to access them safely and without interruption. Consistent with our...
by John Conrad | Apr 6, 2020 | COVID, Member News
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19 Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX:CSL/USOTC:CSLLY) and...
by John Conrad | Mar 31, 2020 | COVID, Member News
BioLife Plasma Services, part of Takeda, has implemented a unique protocol for collecting plasma from healthy individuals who have recovered from COVID-19 to enable development of a potential therapy for COVID-19, made from human plasma. You can read more about this...
by John Conrad | Mar 5, 2020 | COVID
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today will share with members of the United States Congress that it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with...